Author: Excellergy, Inc.

Posted Date:

March 27, 2026

Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors

Excellergy, Inc.

March 27, 2026
Excellergy Presents New Data at 2026 AAAAI Annual Meeting Demonstrating Rapid and Sustained Allergic Effector Cell Control and Announces First Subjects Dosed in Phase 1 DISARM Trial

Excellergy, Inc.

February 27, 2026